National Clinical Labs

National Clinical Labs was paid $6.17M by Medicaid between Oct 2020 and May 2024, across 7 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 56% of everything it billed.

33Billing provider infoNATIONAL CLINICAL LABS
LISLE, IL 60532

33aNPI1053869628assigned 09/13/2016

33bProvider typeClinical Medical Laboratory

28Total paid$6.17M

24GClaims157,243

24DCodes billed7

24AFirst – last monthOct 2020 – May 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in Illinois

Rank by total paid#30 of 235

Median peer was paid$123K

This provider vs. median50×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	4,993	$283K
2021	25,809	$951K
2022	121,277	$4.72M
2023	4,757	$194K
2024incomplete	407	$18K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	56%	47,117	23,575	$3.46M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	19%	51,698	27,099	$1.15M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	16%	41,243	21,703	$981K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	8.2%	12,669	10,077	$503K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	398	278	$38K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	706	436	$32K
99072		<1%	3,412	2,267	$480.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialNAVEED, SYED (PRESIDENT)

Same official

Other billing entities under NAVEED, SYED

Full network →

Provider	Location	Paid
Texas Physicians Primary Care, PLLC	Mesquite, TX	$4.83M
Genesis Diagnostic Services INC	Farmers Branch, TX	$23K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.